- Home
- MDIA vs ITRM Comparison
MDIA vs ITRM Comparison
Compare MDIA & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- ITRM
- Stock Information
- Founded
- MDIA 2019
- ITRM 2015
- Country
- MDIA United States
- ITRM Ireland
- Employees
- MDIA N/A
- ITRM N/A
- Industry
- MDIA Broadcasting
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- MDIA Consumer Discretionary
- ITRM Health Care
- Exchange
- MDIA Nasdaq
- ITRM Nasdaq
- Market Cap
- MDIA 61.4M
- ITRM 49.5M
- IPO Year
- MDIA N/A
- ITRM 2018
- Fundamental
- Price
- MDIA $1.20
- ITRM $1.67
- Analyst Decision
- MDIA
- ITRM Strong Buy
- Analyst Count
- MDIA 0
- ITRM 1
- Target Price
- MDIA N/A
- ITRM $5.00
- AVG Volume (30 Days)
- MDIA 103.6K
- ITRM 1.6M
- Earning Date
- MDIA 12-24-2024
- ITRM 11-14-2024
- Dividend Yield
- MDIA N/A
- ITRM N/A
- EPS Growth
- MDIA N/A
- ITRM N/A
- EPS
- MDIA N/A
- ITRM N/A
- Revenue
- MDIA $69,296,000.00
- ITRM N/A
- Revenue This Year
- MDIA N/A
- ITRM N/A
- Revenue Next Year
- MDIA N/A
- ITRM N/A
- P/E Ratio
- MDIA N/A
- ITRM N/A
- Revenue Growth
- MDIA 94.96
- ITRM N/A
- 52 Week Low
- MDIA $0.40
- ITRM $0.81
- 52 Week High
- MDIA $6.86
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- MDIA 44.86
- ITRM 43.85
- Support Level
- MDIA $1.10
- ITRM $1.78
- Resistance Level
- MDIA $1.35
- ITRM $1.95
- Average True Range (ATR)
- MDIA 0.11
- ITRM 0.31
- MACD
- MDIA -0.00
- ITRM -0.11
- Stochastic Oscillator
- MDIA 26.53
- ITRM 3.23
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.